—

Orion Oyj B (ORNBV.HE) — the peer cohort

As of 2026-10-15 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Orion Oyj B ranks 6 of 11 in its cohort on the Closelooknet composite (62/100) — the cohort is led by Halozyme Therapeutics Inc at 75/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
ORNBV.HE Orion Oyj B 62 83 83 32 ok 0.9%
LLY Eli Lilly and Company 64 80 91 27 bull 6.5%
ORNAV.HE Orion Oyj A 62 82 83 32 ok 1%
SAN.PA Sanofi SA 57 39 69 60 bull 16.8%
NVO Novo Nordisk A/S 55 22 86 74 bear 38.4%
GSK GlaxoSmithKline PLC ADR 53 34 79 57 info 18.4%
GRF.MC Grifols S.A. 49 61 42 78 info 13.8%
HALO Halozyme Therapeutics Inc 75 98 94 47 ok 0.7%
DXCM DexCom Inc 66 87 80 34 watch 9.8%
ARGX.BR Argen-X 64 64 75 28 info 18%
ONC BeiGene, Ltd. 64 84 63 30 ok 2.9%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-15

Quick answers

Who are Orion Oyj B's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Orion Oyj A (ORNAV.HE), Sanofi SA (SAN.PA), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC ADR (GSK), Grifols S.A. (GRF.MC), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM) and others.

How does ORNBV.HE score against its peers?

Orion Oyj B's composite reads 62/100, ranking 6 of 11 in its cohort as of 2026-10-15; the cohort's highest composite is Halozyme Therapeutics Inc at 75/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.